Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

2.920 -0.300 (-9.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,481
Open 3.020
Bid (Size) 2.900 (300)
Ask (Size) 2.970 (100)
Prev. Close 3.220
Today's Range 2.910 - 3.160
52wk Range 2.530 - 152.25
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Via ACCESS Newswire
News headline image
Jaguar Health Compliant with Nasdaq Bid Price Rule
Via ACCESS Newswire

Performance

YTD
-91.6%
-91.6%
1 Month
-10.2%
-10.2%
3 Month
-87.3%
-87.3%
6 Month
-91.8%
-91.8%
1 Year
-98.0%
-98.0%

More News

Read More
News headline image
Jaguar Health (JAGX) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
Jaguar Health Inc (NASDAQ:JAGX) Swings to Profit on Licensing Deal, But Market Sells the News ↗
Via Chartmill
News headline image
Jaguar Health Reports 2025 Financials
Via ACCESS Newswire
News headline image
Jaguar Health Reports First Quarter 2026 Financials
Via ACCESS Newswire
News headline image
Jaguar (JAGX) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
Via ACCESS Newswire
News headline image
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
Via ACCESS Newswire
News headline image
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Via ACCESS Newswire
These stocks are moving in today's session ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
Via ACCESS Newswire
News headline image
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Via ACCESS Newswire
News headline image
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Via ACCESS Newswire
News headline image
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Via ACCESS Newswire
News headline image
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
Via ACCESS Newswire
News headline image
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
Via ACCESS Newswire
News headline image
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Via ACCESS Newswire
News headline image
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Via ACCESS Newswire
News headline image
FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Via ACCESS Newswire
News headline image
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
Via ACCESS Newswire
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire

Frequently Asked Questions

Is Jaguar Health, Inc. - Common Stock publicly traded?
Yes, Jaguar Health, Inc. - Common Stock is publicly traded.
What exchange does Jaguar Health, Inc. - Common Stock trade on?
Jaguar Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jaguar Health, Inc. - Common Stock?
The ticker symbol for Jaguar Health, Inc. - Common Stock is JAGX on the Nasdaq Stock Market
What is the current price of Jaguar Health, Inc. - Common Stock?
The current price of Jaguar Health, Inc. - Common Stock is 2.920
When was Jaguar Health, Inc. - Common Stock last traded?
The last trade of Jaguar Health, Inc. - Common Stock was at 06/03/26 04:00 PM ET
What is the market capitalization of Jaguar Health, Inc. - Common Stock?
The market capitalization of Jaguar Health, Inc. - Common Stock is 500.34M
How many shares of Jaguar Health, Inc. - Common Stock are outstanding?
Jaguar Health, Inc. - Common Stock has 500M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.